News Release

2021.11.22 Other
Products to solve issues for living in Space and living on Earth “Fixpace®” Notification to be used in the International Space Station Hisamitsu
2021.10.14 lR Information
Notification Regarding Application for Selection of “Prime Market” Under the New Market Segments
2021.10.14 lR Information
Notification Regarding Concerning the Decision of Matters Relating to Acquisition of Company’s Own Shares
2021.10.14 lR Information
FY02/2022 Q2 Results Earnings Release Presentation
2021.10.04 Other
Hisamitsu Pharmaceutical Online Sales “Hisamitsu® Iki-Iki Online” Announcement of Starting Pharmaceutical Product Sales
2021.09.21 Other
Announcement of Investment in GAIA Biomedicine, a Bio-Venture from Kyushu University in Japan
2021.09.17 Management and Personnel
Announcement regarding Establishment of “the 7th Medium-term Management Policy” (Presentation Material)
2021.09.17 Management and Personnel
Announcement regarding Establishment of “the 7th Medium-term Management Policy”
2021.08.31 Other
Notice regarding Support for The Disaster of The Torrential Rains in August 2021
2021.08.27 Other
Notice regarding Providing Relief Supplies in Response to The Torrential Rains in August 2021
2021.08.25 Ethical Drugs
Notification of approval for manufacturing and marketing approval of the additional indications of cancer pain relief for pediatric patients of FENTOS® Tapes (Transdermal, pain management patch, Development code: HFT-290) in Japan Hisamitsu
2021.08.20 Ethical Drugs
Notification of application for manufacturing and marketing approval of the additional indications of “low back pain, humeroscapular periarthritis, cervico-omo-brachial syndrome and tenosynovitis” for ZICTHORU® Tapes (Transdermal, pain treatment NSAID patch, development code: HP-3150) in Japan
2021.08.12 Other
Notification of Hisamitsu Pharmaceutical Co., Inc. receiving Administrative Disposition from Saga Prefecture
2021.07.30 Ethical Drugs
Notification of Transfer of Marketing Rights for ORAVI® Mucoadhesive Tablets 50mg for Oropharyngeal Candidiasis
2021.07.26 lR Information
Notice regarding Determination of Details of Issuance of Stock Compensation-Type Share Options (Stock Acquisition Rights)
2021.07.08 lR Information
FY02/2022 Q1 Results Earnings Release Presentation
2021.07.08 lR Information
Notice regarding Issuance of Stock Compensation-Type Share Options (Stock Acquisition Rights)
2021.05.28 Other
Signing of Partnership Agreement with Saga Prefecture and Saga Sports Association Promotion of “SAGA Sports Pyramid Design”
2021.05.28 lR Information
Approach to and Policy on Reduction of Investment Unit, etc.
2021.05.27 Management and Personnel
Executive Appointments
2021.05.19 Ethical Drugs
Notification of marketing of ZICTHORU® Tapes for “cancer pain” in Japan (Transdermal, pain treatment NSAID patch)
2021.05.18 Other
Salonpas® Named the World’s No. 1 OTC Topical Analgesic Patch Brand for the Fifth Consecutive Year
2021.04.27 Research and Development
Notification of the results of the Phase Ⅲ clinical study of HP-5070 in Japan (primary palmar hyperhidrosis treatment drug)
2021.04.08 lR Information
FY02/2021 Q4 Results Earnings Release Presentation
2021.04.08 Management and Personnel
Executive Appointments
2021.04.02 Other
Contributions to The Japan Olympic Committee (JOC) and The Japan Paralympic Committee (JPC)
2021.03.31 Other
Notice regarding Designing of “HELLO! eco!” Logo and The Launch of its Website Products that meet the environmental standards set by the Company are labeled with the logo.
2021.03.23 Ethical Drugs
Notification of approval for manufacturing and marketing approval of ZICTHORU® TAPES for “cancer pain” in Japan (Transdermal, pain treatment NSAID patch, development code: HP-3150)
2021.03.23 lR Information
Notice regarding Revision of Earnings Forecast
2021.02.24 Subsidiaries and Affiliated Companies
Noven Pharmaceuticals, Inc. press release : Noven submits New Drug Application for INVESTIGATIONAL dextroamphetamine transdermal system for ADHD
2021.02.12 Other
Notice regarding The Decision to Contribute to Supporting Organizations in FY 2020 through Hisamitsu Pharmaceutical Co., Inc. Hot Heart Club
2021.01.20 Ethical Drugs
Notice regarding Obtaining Approval of Partial Change of Approved Matters of “Mohrus® Paps XR 120 mg and 240 mg”, Transdermal Analgesic Anti-Inflammatory Patches
2021.01.13 lR Information
FY02/2021 Q3 Results Earnings Release Presentation
2021.01.04 Research and Development
Notification of the commencement of the Phase III clinical study of HP-5000 in the U.S. (Transdermal, pain relief and anti-inflammatory patch)

PAGETOP